Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful vigilantly but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be being used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of my past several shares. My 1st CytoDyn article, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire employment interview which I came away with a poor opinion of the company.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, though the disappointment hasn’t been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise and connected intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) as well as the very first new drug program endorsement ($5 million), as well as royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many indications and many therapies, it has this single therapies as well as a “broad pipeline of indications” because it puts it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an active business with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple presentations.

Could all this be smoke cigarettes and mirrors? That is a question I have been asking myself with the very start of my interest in this particular organization. Judging by the multiples of a huge number of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am much from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *